Fortrea (FTRE)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$23.14-10.59%
Close 2026-10-29 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put FTRE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is contracting — down about 2% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 13% growth a year, above the roughly 2% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 52% in its worst 12-month stretch.
View RiskFTRE's case rests on stabilizing and growing revenue, alongside improving adjusted EBITDA guidance. Recent non-GAAP EPS beats support that case, though revenue growth rates are absent. FTRE trades at 30× P/E versus the 21× peer median. The market prices in more growth than our forecast, leaving expectations full. The 35% next-quarter miss probability and premium to peers create specific risks. Peer multiples imply a price about 13% below where it trades. Our standing read remains intact, and this read is provisional.
Trailing returns as of 2026-10-29. FTRE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering FTRE (as of Oct 2026).
Based on 5 Wall Street analysts offering 12-month price targets for FTRE in the last 4 months.
Continue this research
Compare FTRE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| FTRE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 5 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put FTRE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Stabilize and grow revenue
2026 revenue outlook signals stabilization, while higher EBITDA guidance supports margin improvement.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $23.14
The last 12 months of price, then the range of analyst 12-month targets from today’s $23.14.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
M&A could stabilize and grow revenue significantly.
Acquisition supports revenue growth and operational expansion.
Advances: Improve adjusted EBITDA and margin expansion
Earnings improvement indicates progress in adjusted EBITDA.
Advances: Stabilize and grow revenue
Turnaround indicates potential revenue stabilization and growth.